GENFIT Stock Other OTC
Stocks
GNFTF
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded
| Market Cap | 517M 593M 479M 448M 840M 55.94B 846M 5.68B 2.2B 27.53B 2.23B 2.18B 95.6B | P/E 2025 |
-3.06x | P/E 2026 * | 54.6x |
|---|---|---|---|---|---|
| Enterprise Value | 462M 530M 428M 401M 751M 50.01B 756M 5.08B 1.97B 24.62B 1.99B 1.95B 85.48B | EV / Sales 2025 |
2.34x | EV / Sales 2026 * | 4.94x |
| Free-Float |
86.88% | Yield 2025 * |
-
| Yield 2026 * | - |
| 1 day | -3.28% |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.28% | -.--% | - | - | 593M | |
| +1.44% | +1.71% | -10.63% | -9.16% | 42.75B | |
| +0.37% | +9.22% | +308.19% | +562.02% | 34.65B | |
| +2.84% | +3.80% | +6.87% | +34.93% | 30.03B | |
| -1.70% | -7.34% | +8.51% | -22.34% | 28B | |
| -1.90% | +2.47% | +10.18% | +18.13% | 24.83B | |
| +1.22% | +7.06% | - | - | 14.34B | |
| +0.68% | -3.13% | +52.04% | +107.47% | 13.14B | |
| -0.57% | -2.43% | +5.18% | +4.20% | 12.61B | |
| -0.26% | +0.41% | +100.27% | +80.69% | 12.25B | |
| Average | +0.03% | +0.55% | +60.08% | +96.99% | 23.62B | |
| Weighted average by Cap. | +0.73% | +0.91% | +65.06% | +113.03% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 66.82M 76.63M 61.88M 57.93M 109M 7.23B 109M 734M 285M 3.56B 288M 281M 12.36B | 95.2M 109M 88.17M 82.54M 155M 10.3B 156M 1.05B 405M 5.07B 410M 401M 17.61B |
| Net income | -8.3M -9.52M -7.69M -7.2M -13.5M -898M -13.58M -91.22M -35.35M -442M -35.74M -34.98M -1.54B | 18.31M 21M 16.95M 15.87M 29.77M 1.98B 29.95M 201M 77.95M 975M 78.81M 77.12M 3.39B |
| Net Debt | -54.72M -62.76M -50.68M -47.44M -88.98M -5.92B -89.51M -601M -233M -2.91B -236M -231M -10.12B | -46.87M -53.75M -43.41M -40.63M -76.21M -5.07B -76.67M -515M -200M -2.5B -202M -197M -8.67B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
